Surrozen Inc
NASDAQ:SRZN

Watchlist Manager
Surrozen Inc Logo
Surrozen Inc
NASDAQ:SRZN
Watchlist
Price: 12.23 USD 15.76% Market Closed
Market Cap: 39.7m USD
Have any thoughts about
Surrozen Inc?
Write Note

Surrozen Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Surrozen Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Surrozen Inc
NASDAQ:SRZN
Accounts Receivables
$2.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Surrozen Inc
Glance View

Market Cap
39.7m USD
Industry
Biotechnology

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 83 full-time employees. The company went IPO on 2020-11-23. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The firm's product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in the activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancer Engineered for Tissue Specificity (SWEETS), enable to selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. The firm's two lead product candidates include SZN-1326 and SZN-043.

SRZN Intrinsic Value
16.89 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Surrozen Inc's Accounts Receivables?
Accounts Receivables
2.2m USD

Based on the financial report for Dec 31, 2023, Surrozen Inc's Accounts Receivables amounts to 2.2m USD.

What is Surrozen Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
8%

Over the last year, the Accounts Receivables growth was 8%.

Back to Top